Showing results (61-70 of 164) with videos related to

Sort By:
Pageof 17
Blood|October 20, 2011
The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignanciesAnne Bergeron, Raphaël Porcher, Annie Sulahian, et al.
Blood|May 27, 2006
Frequent antibody production against RARalpha in both APL mice and patientsMarie Robin, Juliette Andreu-Gallien, Marie-Helene Schlageter, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2015
Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune EvasionZena Khaznadar, Nicolas Boissel, Sophie Agaugué, et al.
Haematologica|December 31, 2016
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des Myélodysplasies</i>Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, et al.
Blood Advances|April 18, 2025
Prognostic Significance of Monocytic-like Phenotype in AML patients treated with Venetoclax and AzacytidineLin-Pierre Zhao, Typhaine Dumas-Rivero, Lauren Barette, et al.
The Lancet. Haematology|April 12, 2016
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 studyCéline Berthon, Emmanuel Raffoux, Xavier Thomas, et al.
Oncotarget|March 25, 2014
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trialAline Renneville, Raouf Ben Abdelali, Sylvie Chevret, et al.
Blood|March 25, 2015
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cellsHiba El Hajj, Zeina Dassouki, Caroline Berthier, et al.
Haematologica|August 5, 2018
Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trialJuliette Lambert, Cécile Pautas, Christine Terré, et al.
Medical Mycology|July 17, 2013
Invasive infections due to Candida norvegensis and Candida inconspicua: report of 12 cases and review of the literatureJuliette Guitard, Adéla Angoulvant, Valérie Letscher-Bru, et al.
Pageof 17